A randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. - ACCEPT-D

CONSORZIO MARIO NEGRI SUD0 个研究点开始时间: 2007年6月11日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Written informed consent to participate in this study; Clinical diagnosis of type 1 or type 2 diabetes, irrespective of diabetes treatment; Need for statin treatment: - patients already receiving statin therapy irrespective of their actual LDL cholesterol and total cholesterol levels or - patients not currently on statin treatment with LDL-cholesterol levels >=110 mg/dL persisting after three months of dietary advise; Ability and willingness to comply with all study requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Previous major vascular events (non-fatal myocardial infarction, non-fatal stroke, angina, transient ischemic attack, revascularization procedures, peripheral vascular disease); Unstable metabolic control (HbA1c >14.0%); Any condition requiring elective treatment with aspirin; Contraindications to aspirin; Contraindications to simvastatin; Chronic therapy with non steroidal antiinflammatory drugs; Presence of any life-threatening condition; Child-bearing potential (pre-menopausal women not using reliable contraception); History of active substance or alcohol abuse within the last year.

发起方

CONSORZIO MARIO NEGRI SUD